Search
Hexobarbital
go.drugbank.com/drugs/DB01355ExperimentalA barbiturate that is effective as a hypnotic and sedative.
Chondroitin sulfate
go.drugbank.com/drugs/DB09301ApprovedInvestigationalNutraceuticalDepending on the predominating disaccharide unit, it will present different biological activities.
Turoctocog alfa
go.drugbank.com/drugs/DB09109ApprovedTuroctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally occurring B-domain. Turoctocog a...
Patent Blue
go.drugbank.com/drugs/DB13967ApprovedInvestigationalPatent blue is aniline dye and it is one of the most common dyes used. It is a sodium or calcium salt of diethylammonium hydroxide inner salt. It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-...
Dextrothyroxine
go.drugbank.com/drugs/DB00509ApprovedWithdrawnThe major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (monoiodotyrosine) and the coupling of iodotyrosines (diiodotyrosine) in the thyroglobulin. Thyroxine is released from thyroglobul...
Pracinostat
go.drugbank.com/drugs/DB05223InvestigationalPracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with...
Type 1 Diabetes Mellitus
go.drugbank.com/conditions/DBCOND0029465Drugs: Captopril · Donislecel · Insulin degludec · Insulin detemir · Insulin glargine · Insulin glulisine +5 moreHospitalizations
go.drugbank.com/conditions/DBCOND0105072Acoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigationalAcoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis. Similar to the previously developed tafamidis, acoramidis is used to stabilize TTR in its tetrameric form, preventing the formatio...
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalDabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic n...